Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 10 2022 - 7:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
May 10, 2022
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K
On May 10, 2022, Immatics N.V. (the “Company”)
announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER®) IMA401 for patients with recurrent
and/or refractory solid tumors. IMA401 is the most advanced product candidate from Immatics’ TCR Bispecific pipeline targeting an
HLA-A*02-presented peptide derived from both MAGEA4 and MAGEA8. TCER® IMA401 will be developed in collaboration with Bristol Myers
Squibb. Immatics is responsible for conducting the Phase 1 clinical trial. The primary objectives of the clinical trial (NCT#05359445)
are to determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) for IMA401 in biomarker-positive (HLA-A*02:01
and MAGEA4/8) patients with recurrent and/or refractory solid tumors. Secondary objectives are to characterize safety and tolerability,
evaluate initial anti-tumor activity and assess pharmacokinetics of IMA401. The Phase 1 trial consists of a dose-escalation (Phase 1a)
portion that will be followed by a dose-expansion (Phase 1b) portion to treat patients at the recommended dose level. The trial is planned
to be conducted at up to 15 centers in Germany, with the first site already being initiated. The Phase 1 trial is designed to enroll approximately
50 patients.
In connection with the initiation of the Phase
1 clinical trial, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1, and made available an updated
investor presentation on its website, a copy of which is attached hereto as Exhibit 99.2. The fact that this presentation is being made
available and filed herewith is not an admission as to the materiality of any information contained in the presentation. The information
contained in the presentation is being provided as of May 10, 2022 and the Company does not undertake any obligation to update the presentation
in the future or to update forward-looking statements to reflect subsequent actual results.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than Exhibits 99.1
and 99.2) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351 and 333-240260) of
Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished.
EXHIBIT INDEX
Exhibit No. |
Description |
99.1 |
Press release dated May 10, 2022 |
99.2 |
Presentation dated May 10, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
IMMATICS N.V. |
Date: May 10, 2022 |
|
|
By: |
/s/ Harpreet Singh |
|
Name: |
Harpreet Singh |
|
Title: |
Chief Executive Officer |
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024